search
Back to results

Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy?

Primary Purpose

Endometrial Cancer, Endometrial Neoplasms, Endometrial Hyperplasia

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Ultrasound guided biopsy
Sponsored by
Imperial College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Endometrial Cancer focused on measuring Ultrasound, Biopsy, Endometrial cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

All women presenting to rapid access gynaecology clinic with postmenopausal bleeding or intermenstrual bleeding or referred with a confirmed diagnosis of endometrial cancer.

Exclusion criteria:

Anyone lacking capacity. <18years old. Pregnant.

Sites / Locations

  • Queen Charlotte and Hammersmith HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Women needing endometrial biopsy

Arm Description

All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.

Outcomes

Primary Outcome Measures

Accuracy of histological diagnosis using ultrasound guided biopsy.
Accuracy of histological diagnosis using ultrasound guided biopsy.

Secondary Outcome Measures

Patient satisfaction of Ultrasound guided biopsy
Visual analogue score will be given to patients post procedure to assess tolerability of the procedure

Full Information

First Posted
June 30, 2017
Last Updated
February 11, 2021
Sponsor
Imperial College London
search

1. Study Identification

Unique Protocol Identification Number
NCT03207126
Brief Title
Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy?
Official Title
Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy in the Detection of Endometrial Cancer?
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 13, 2017 (Actual)
Primary Completion Date
December 20, 2021 (Anticipated)
Study Completion Date
January 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Aim: Assess accuracy of histological diagnosis using ultrasound guided biopsy for women with suspected endometrial cancer (as an alternative to hysteroscopy guided biopsy). All women presenting to clinic with suspected endometrial cancer will have an internal ultrasound. If the endometrial lining is thickened an endometrial biopsy will be performed. This can sometimes be done in an outpatient clinic, or sometimes a hysteroscopy and biopsy is needed (on a different day). Hysteroscopy guided biopsy has the advantage of enabling the clinician to perform directed biopsies under vision. Ultrasound guided biopsy is a ubiquitous procedure when used elsewhere in the body however it is not routinely used in this context. It does have the advantage of being easily performed on the same day as the first consultation. In this pilot study we will assess the diagnostic ability and tolerability of ultrasound guided biopsy of women with suspected cancer, as an alternative to hysteroscopy guided biopsy.
Detailed Description
Aims: Assess accuracy of histological diagnosis using ultrasound guided biopsy for women with suspected endometrial cancer (as an alternative to hysteroscopy guided biopsy). Background: Endometrial cancer is a tumour originating in the endometrium (womb lining); it is the most common gynaecological cancer in the UK. Although routine management for these women does vary, in general a screening test is performed, typically a pelvic (internal) ultrasound to assess the endometrium (womb lining). In cases where the endometrial thickness is above the threshold for investigation - an endometrial biopsy (sampling cells from the womb lining) is indicated. The biopsy can be taken blindly or under scan or hysteroscopic guidance. Hysteroscopy, the insertion of a small camera into the womb to visualise the womb lining allows direct visualization of the cavity. This usually occurs at a separate consultation in an outpatient setting or under general anaesthesia. In theory an ultrasound-guided biopsy using a very fine Bettocchi forceps could be used instead of hysteroscopy- guided biopsies of the endometrium. The technique of ultrasound-guided biopsy is ubiquitous when used elsewhere in the body. It is frequently used to provide histological diagnosis of pelvic masses, (presumed ovarian origin), both abdominally (scanning of the tummy) and transvaginally (internally). Potentially ultrasound guided biopsies could be used as a cheaper, faster and less painful alternative to a hysteroscopy directed biopsies. This pilot study will be the first to assess the diagnostic ability of ultrasound guided biopsy in the assessment of women with suspected endometrial cancer. The study: All women will receive a pelvic (internal) ultrasound as per routine care. If the endometrium (womb lining) is thickened >4mm on ultrasound they will require an endometrial biopsy. Usually this will be a pipelle. In cases where the pipelle biopsy cannot be performed in clinic due to poor tolerance, insufficient material or focal lesions a hysteroscopy guided biopsy will be required (local or GA). In this case, the patients will be offered an ultrasound (USS) guided biopsy in the first instance, this will be performed at the same time in clinic. The biopsy will be taken under scan guidance using a very fine forceps such as Bettochi forceps. These forceps are used routinely during hysteroscopy so whilst the instruments are common the application is novel. The biopsy results of this will be sent for standard histology. If the results are inadequate patients will be sent for standard hysteroscopy and biopsy. Patients will also be asked to assess tolerability of the procedure using a visual analogue score.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Cancer, Endometrial Neoplasms, Endometrial Hyperplasia, Endometrial Polyp
Keywords
Ultrasound, Biopsy, Endometrial cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Women needing endometrial biopsy
Arm Type
Other
Arm Description
All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
Intervention Type
Diagnostic Test
Intervention Name(s)
Ultrasound guided biopsy
Intervention Description
For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
Primary Outcome Measure Information:
Title
Accuracy of histological diagnosis using ultrasound guided biopsy.
Description
Accuracy of histological diagnosis using ultrasound guided biopsy.
Time Frame
1.5 years
Secondary Outcome Measure Information:
Title
Patient satisfaction of Ultrasound guided biopsy
Description
Visual analogue score will be given to patients post procedure to assess tolerability of the procedure
Time Frame
1.5 years

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Study is looking at endometrial cancer
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All women presenting to rapid access gynaecology clinic with postmenopausal bleeding or intermenstrual bleeding or referred with a confirmed diagnosis of endometrial cancer. Exclusion criteria: Anyone lacking capacity. <18years old. Pregnant.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Diana Marcus, MB BS
Phone
020 7589 5111
Email
d.marcus16@imperial.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Joseph Yazbek
Email
joseph.yazbek@nhs.net
Facility Information:
Facility Name
Queen Charlotte and Hammersmith Hospital
City
London
ZIP/Postal Code
W12 0HS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana Marcus, MB BS
Email
d.marcus16@imperial.ac.uk
First Name & Middle Initial & Last Name & Degree
Sadaf Ghaem-Maghami, FRCOG PhD
First Name & Middle Initial & Last Name & Degree
Jospeh Yazbek, FRCOG

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy?

We'll reach out to this number within 24 hrs